Post-earnings recap
Reported
Wed, May 11, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axsome Therapeutics did not meet consensus expectations for EPS, but the stock still rose by 0.81%. This increase suggests that investors are optimistic about the company's ongoing clinical trials and future potential. The lack of revenue data and guidance indicates uncertainty, but management's positive outlook may have reassured some investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed optimism about the company's clinical developments. However, they did not offer specific guidance for future performance.
Management highlighted ongoing progress in their clinical trials.
They emphasized their commitment to advancing their pipeline.
No specific financial guidance was provided for the upcoming quarters.